Alternate-day alternating monotherapy (q48h) versus daily concomitant atorvastatin–fenofibrate in adults with type 2 diabetes and mixed dyslipidemia: a 12-week randomized non-inferiority trial
Soheil Shahramirad, Milad Rezvani, Roya Jahanbazi, Mohammadreza Vataniman, Nasrin Razavianzadeh. Alternate-day alternating monotherapy (q48h) versus daily concomitant atorvastatin–fenofibrate in adults with type 2 diabetes and mixed dyslipidemia: a 12-week randomized non-inferiority trial. // BMC Endocrine Disorders. – 2026. – DOI: 10.1186/s12902-025-02156-z. – URL: https://doi.org/10.1186/s12902-025-02156-z
Soheil Shahramirad, Milad Rezvani, Roya Jahanbazi, Mohammadreza Vataniman, & Nasrin Razavianzadeh (2026). Alternate-day alternating monotherapy (q48h) versus daily concomitant atorvastatin–fenofibrate in adults with type 2 diabetes and mixed dyslipidemia: a 12-week randomized non-inferiority trial. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-025-02156-z
Soheil Shahramirad, et al. “Alternate-day alternating monotherapy (q48h) versus daily concomitant atorvastatin–fenofibrate in adults with type 2 diabetes and mixed dyslipidemia: a 12-week randomized non-inferiority trial.” BMC Endocrine Disorders, 2026. doi:10.1186/s12902-025-02156-z.
@article{Shahramirad2026,
title = {Alternate-day alternating monotherapy (q48h) versus daily concomitant atorvastatin–fenofibrate in adults with type 2 diabetes and mixed dyslipidemia: a 12-week randomized non-inferiority trial},
author = {Shahramirad, Soheil and Rezvani, Milad and Jahanbazi, Roya and Vataniman, Mohammadreza and Razavianzadeh, Nasrin},
journal = {BMC Endocrine Disorders},
year = {2026},
doi = {10.1186/s12902-025-02156-z},
url = {https://doi.org/10.1186/s12902-025-02156-z}
}